Stryker (SYK) Receives a Hold from Goldman Sachs

In a report released today, David Roman from Goldman Sachs maintained a Hold rating on Stryker, with a price target of $357.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Roman covers the Healthcare sector, focusing on stocks such as Omada Health, Inc., Boston Scientific, and Insulet. According to TipRanks, Roman has an average return of -4.9% and a 37.65% success rate on recommended stocks.

In addition to Goldman Sachs, Stryker also received a Hold from TipRanks – Anthropic’s Anthropic Medical – Devices in a report issued on March 24. However, yesterday, Citi maintained a Buy rating on Stryker (NYSE: SYK).

Based on Stryker’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.17 billion and a net profit of $849 million. In comparison, last year the company earned a revenue of $6.44 billion and had a net profit of $546 million

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in February 2026, Ronda Stryker, a Director at SYK sold 500,000.00 shares for a total of $181,717,233.87.